Solving clinical trial delays: Three things to do now
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Solving clinical trial delays: Three things to do now

21 Sep 2021 (Last Updated October 21st, 2021 17:04)

Sponsored by Aposave Sponsored by Visit Company
Solving clinical trial delays: Three things to do now

Clinical trials face delays all too often. But in a competitive industry, where time-to-market is everything, keeping these delays to a minimum could be the difference between a market-leading product and one destined for the shadows. McKinsey calculates that a second-to-market product will have a 6% market share disadvantage ten years later, showing the long-lasting impact a delay could have.

A well-known culprit is patient recruitment, which is often slower than trial schedules anticipate. Securing adequate stock of comparator drugs is another tricky area where complications often result in expanded timelines. Pharmaceutical Technology spoke to Ian Hoban, business development director at Aposave, the pharmaceutical services division of Abacus Medicine, to find out what sponsors can do to avoid delays.

Don’t leave it too late

If you haven’t started developing a rigorous comparator sourcing strategy, but have already developed an initial patient recruitment strategy, it’s time to urgently address the gap. Often, sponsors leave it too close to the start of the trial to place their orders. Being hit with a longer-than-expected lead time or a customs-related hold up at this stage could be detrimental.

“If delays happen, there’s things you can do  such as potentially source smaller quantities up front as a solution for the initial demand while you slowly build up the inventory for the large bulk of the trial,” says Hoban. “That can have a knock-on effect though; if you’re sourcing smaller quantities, they can have shorter expiry dates, meaning they’re at risk of not making it through to the end of the trial.”

A problem that’s even harder to solve is missing documentation. According to Hoban, some sponsors go wrong by focusing too greatly on getting a good deal regarding the acquisition cost of the comparator. If the product doesn’t come with the necessary documentation, it could cost you more in the long run.

“It can cause all sorts of delays down the line,” Hoban adds. “The documentation might be important in moving it from one market to another. The medicine’s usage in a global trial could be compromised by that missing data.”

Choosing the right market to source from is also key. While small markets may work well for early phase trials, increasing the volume to supply a late-phase trial could account for a significant portion of the total patient demand in that market. “You’re never going to be able to sustainably source those volumes in a small market. When doing a Phase III study, you need to look at bigger markets or go direct-to-manufacturer,” suggests Hoban.

Stay vigilant

Having completed a thorough initial sourcing plan at the early stage of your trial design, it’s critical to make sure it is regularly reviewed and challenged throughout the life of the project. The dynamic environment of pharmaceuticals often throws up a change of circumstances that makes what was previously achievable suddenly very difficult, if not impossible.

For instance, some medicines become harder to source over time as demand increases both from other trials and existing patient markets. Meanwhile, as products approach the end of their life cycle, the manufacturer’s loss of exclusivity strategy may cause previously available presentations to be phased out – something currently seen with Eylea vials, for example.

Working closely with your provider

Sponsors should work closely with their key supply partners to ensure they receive regular reviews of the market dynamics for the molecule in question, and that appropriate risk analysis and strategy adjustments are carried out.

For Aposave, having ongoing discussions with the client and providing them with the information they need to make well-informed, strategic decisions through the duration of the trial, is key. Behind this is the company’s market analytics tools, which enables Aposave to rapidly assess predictive insights, prices, next available batches, suppliers with access, and the markets where CoAs will be available.

In addition, Aposave’s parent company, Abacus Medicine,  purchases significant quantities of key specialty medicines on an ongoing basis, providing Aposave with unrivalled access to a dynamic source of the medicines needed to keep trials on track. The combination of Aposave’s experience, procurement resources, and state-of-the-art analytics has created a unique clinical trials solution for the next generation of pharmaceutical products.

To find out more, download the whitepaper below.

Free Case Study

Overcoming sourcing challenges for EU clinical trials supplies

When a large pharmaceutical company required a unique solution for the sourcing of its comparator medicines, Aposave was well-placed to step in with its new-generation pharma services. The client’s clinical development strategy demanded a significant supply of reference products with maximum diversity of batch, expiry, and origin conditions – no problem for a service provider with Aposave’s expertise and resources.

This whitepaper explores the comparator sourcing challenges faced by Aposave’s client and how the European medicine market, accessed via Aposave’s valued clinical trial solutions, is able to keep their busy clinical pipeline progressing as planned. To read the full story and find out more about Aposave, download below.

By clicking the “Submit” button above, you accept the Terms & Conditions and acknowledge that your data will be used as described in the Aposave Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.